Relationship on new statin use and the risk of hepatocellular carcinoma (HCC) in patients with incident type 2 diabetes mellitus (T2DM), who might be at the risk of developing HCC, is uncertained. A nationwide population-based nested case-control study was conducted within the National Health Insurance Service National Sample Cohort 2002-2013 in Korea. Newly prescribed statin after newly diagnosed T2DM was defined as statin use. Controls were matched to case patients on age, sex, follow-up time, and the date of diabetes diagnosis at a five-to-one ratio. Odds ratios (ORs) for associations of statin use with HCC were calculated using conditional logistic regression. After at least a 5-year HCC-free period, there were 229 incident HCC cases and 1,145 matched controls from 47,738 patients with incident diabetes. Of these 229 incident HCC cases, 27 (11.8%) were statin users, whereas 378 (33.0%) were statin users among 1,145 controls. Statin use was associated with a reduced risk of HCC development (adjusted OR [AOR]5 0.36, 95% confidence interval [CI] 0.22-0.60) after adjustment for chronic viral hepatitis, liver cirrhosis, alcoholic liver disease, previous cancer, aspirin use, insulin use, sulfonylurea use, metformin use, thiazolidinedione use, history of chronic obstructive pulmonary disease, Charlson comorbidity score, household income level, and residential area. Risk reduction was accentuated with an increase of cumulative defined daily doses (cDDD) compared with non-users (AORs 0.53, 0.36, 0.32, and 0.26 in 60, 60-180, 181-365, and >365cDDD, respectively; P for trend <0.0001). The risk reduction was apparent in the presence of liver disease (AOR 5 0.27, 95% CI 0.14-0.50), including heterogeneous groups of clinical diagnosis of liver disease, but not significant in the absence of liver disease (AOR 5 0.64, 95% CI 0.32-1.29). Among patients with new onset T2DM, statin use before HCC diagnosis may have a beneficial inhibitory effect on HCC development in a dose-dependent manner, especially in individuals with liver disease.
dyslipidemia and related cardiovascular complications in patients with diabetes compared to subjects without diabetes. 12 Therefore, the rate of cholesterol-lowering 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) use among patients with diabetes is higher than among individuals without diabetes. 13, 14 The prevalence of dyslipidemia in subject with type 2 diabetes has been steadily rising in Korea, 15 and 49.5% of adults with type 2 diabetes had dyslipidemia and treated with lipid lowering medication, which was 5-fold higher compared to 9.7% of non-diabetic adults in the Korean population. 16 Collectively, our choice of study among patients with diabetes was related to the known higher likelihood of developing HCC as well as using statins to treat commonly found dyslipidemia.
Statins have been proposed to be beneficial in cancer prevention, including melanoma and cancer of the colon, breast and prostate as well as HCC. [17] [18] [19] [20] [21] [22] Statins are selectively distributed in the liver as target organ, and the majority of their beneficial effects appear to be mediated primarily by modulating lipid metabolism, mainly in the liver. 23, 24 However, the association between statin use and the risk of HCC in patients with diabetes is poorly understood. Of interest here, particularly, are studies on the association between statin use and HCC development in patients with diabetes in a longitudinal nested control setting; however, few such reports exist. 18, 25 Moreover, those that had been conducted were of Western rather than Asian populations, although HCC incidence is the highest in the latter. Also, these studies did not control statin use before the diagnosis of diabetes or throughout the duration of diabetes. This led us to evaluate HCC development after statin use in patients who had been newly diagnosed with type 2 diabetes mellitus (T2DM), which is associated with high incidence of HCC, in a nationwide longitudinal nested case-control setting of Asian populations.
Methods

Data source
We used a data set obtained from the National Health Insurance Service National Sample Cohort (NHIS-NSC) [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] in Republic of Korea, which was described in the previous study. 26 It is a stratified, random sample composed of 2% of the South Korean population, and had a baseline of 1,025,340 individuals in 2002. The information included contains all inpatient and outpatient medical claims data, including personal information, prescription drugs, diagnostic and treatment codes, and primary and secondary diagnosis codes. In addition, the unique de-identified number was linked to mortality information from the Korean National Statistical Office. Under universal medical coverage, all medical claims data are collected by the Korean National Health Insurance Service as the monopolistic health insurer in Korea, so that all individual included in the NHIS-NSC were followed until 2013, unless there was a death or disqualification for National Health Insurance such as emigration. The protocol of this study was approved by the Institutional Review Board (No: 4-2015-0636) at Severance Hospital.
Incident T2DM cohort
Within the NHIS-NSC, from subjects without any prescribed antidiabetic agent including insulin, sulfonylurea, metformin, thiazolidinedione and other oral hypoglycemic agents (meglitinides, dipeptidyl peptidase-4 inhibitors, and alpha-glucosidase inhibitors) in 2002, we selected patients who were prescribed their first antidiabetic agent including insulin, sulfonylurea, metformin, and thiazolidinedione from 2003 to 2012. This was to ensure that all study subjects had at least one antidiabetic agent-free year. 27 We also excluded patients whose first antidiabetic agent was insulin and patients who were <40 years of age at the time of their first antidiabetic prescription as previously described. 27 Thus, patients with type 1 diabetes or advanced patients with T2DM may have been excluded from the cohort. The date of each incident T2DM cohort entry was defined as the date of the first antidiabetic agent prescription of insulin, sulfonylurea, metformin or thiazolidinedione. The last date of follow-up was defined as the date of HCC diagnosis, death, disqualification from Korean NHI, or 31 December 2013, whichever came first. Ultimately, the incident T2DM cohort consisted of 47,738 incident T2DM patients.
Case-control patient selection from the incident T2DM cohort
In this nested case-control study with risk-set sampling (or incidence-density sampling), control patients were chosen from the set of patients in the incident T2DM cohort who were at risk of becoming a case at the time that the case was diagnosed. The primary diagnosis code using the International Classification of Diseases, 10th Revision (ICD-10) was used to identify case patients. 28 What's new?
In a nationwide population-based nested case-control study, the association between statin use and the risk of hepatocellular carcinoma in patients with incident type 2 diabetes mellitus, who might be at the risk of developing hepatocellular carcinoma, was investigated. Initiation of statin in patients with newly diagnosed type 2 diabetes mellitus was associated with a beneficial inhibitory effect on hepatocellular carcinoma development in a dose-dependent manner, especially in individuals with liver disease.
The eligibility criteria for case patients were the following: (i) first-time diagnosis of HCC (ICD C22.0) with at least a prior 5-year HCC-free period, (ii) at least a 1-year HCCfree (latent) period after the time of diabetes diagnosis to take into account a biologically meaningful latency time window, and to minimize reverse causuality, 27, 29 (iii) no prior diagnosis of other liver cancers (intrahepatic bile duct carcinoma, hepatoblastoma, angiosarcoma, and other sarcomas; C22.1-C22.4) prior to the date of HCC diagnosis, (iv) no prior diagnosis of pancreatic or biliary tract cancers (gallbladder, biliary tract and pancreatic cancer; C23-C25) prior to the date of HCC diagnosis, (v) no prior diagnosis of any cancer most likely to metastasize to the liver (stomach, colon, bronchus and lung, and breast; C16, C18-C20, C34, C50) prior to the date of HCC diagnosis in order to be sure to exclude recurrent and metastatic liver cancer, 18 (vi) exclusion of not having any supporting clinical codes indicating the presence of HCC including any liver diagnostic tests (biopsy or arteriography of hepatic artery), any treatments on the liver (hepatectomy, liver transplantation, radiofrequency ablation, arterial embolization, radiotherapy, or chemotherapy), death due to HCC (death code for liver cancer), early death (within 6 months) or admission because of primary diagnosis of HCC (Fig. 1) .
Control patients were randomly selected from the risk set at a 5:1 ratio. Controls and cases were matched based on sex, the 5-year interval age group at the date of diabetes diagnosis, follow-up time, and the date of diabetes diagnosis within a 180-day range. Control patients had to be free of pancreatic or biliary tract cancer, and any cancer most likely to metastasize to the liver, as same as the criteria of case patient selection.
For the subgroup analyses, additional matches according to severity of liver diseases and use of antidiabetic agents were conducted. "Any liver disease" included any acute or chronic disease of the liver (K70-K77), including alcoholic liver disease, toxic liver disease, hepatic failure, chronic hepatitis, fibrosis or cirrhosis of the liver, other infectious and inflammatory liver disease, NAFLD, autoimmune hepatitis, and chronic viral hepatitis (B18), regardless of disease severity. Therefore, patients "without any liver disease" were a relatively homogeneous group, while patients "with any liver disease" are relatively heterogeneous due to the mixture of disease severities. In addition to "any liver disease", further analyses were conducted for subgroups such as those with cirrhosis and those with disease other than cirrhosis.
Use of statins
For all analyses, prescription information before the index date was used to identify drug use. The index date was defined as the date 1 year before the date of HCC diagnosis. Statin use was defined as at least one prescription of statin between the cohort entry and the index date. Patients who had started statin use before the cohort entry were excluded. The same definition of drug use was applied to all types of drugs, including non-antidiabetic drugs. The defined daily dose (DDD), which is the assumed average maintenance dose per day of a drug, recommended by the World Health Organization was used. 19 Total amount of prescribed drug divided by the DDD was presented as cumulative DDD (cDDD) to standardize the drug dosage in different drug types to compare. Therefore, cDDD of statin also indicates the exposed duration of statin use. In addition, specific statins such as atorvastatin, simvastatin, rosuvastatin, pravastatin, pitavastatin, lovastatin and fluvastatin were analyzed individually.
Statistical analysis
Conditional logistic regression was conducted to estimate odds ratios (ORs) and 95% confidence intervals (CIs) to assess the association between statin use and the risk of HCC. In addition to matching variables, we adjusted for history of previous cancer, chronic viral hepatitis (B18), alcoholic liver disease, alcohol-related mental and behavioral disorders (K70, F10), chronic lower respiratory disease other than asthma (J40-J47) and cirrhosis of the liver and related complications (K74, K72.1, K72.9, K76.5-K76.7, I85, I86.4, I98.2). Previous cancer was defined as the presence of other different primary cancers that were diagnosed prior to HCC diagnosis, except for liver cancers (intrahepatic bile duct carcinoma, hepatoblastoma, angiosarcoma, and other sarcomas), pancreatic or biliary tract cancers (gallbladder, biliary tract, and pancreatic cancer), and any cancers most likely to metastasize to the liver (stomach, colon, bronchus and lung, and breast). 18 We also adjusted for the Charlson comorbidity score, antidiabetic medications (insulin, sulfonylurea, metformin and thiazolidinedione), aspirin use, household income and residential area. 30 As there was incomplete information regarding the smoking and alcohol drinking habits of individuals in the NHIS-NSC, we assumed that chronic lower respiratory disease and alcoholic liver disease as well as alcohol-related mental and behavioral disorders could be used as surrogate variables for cigarette smokers and alcohol use, respectively. Covariates were assessed using all information prior to the index date.
In addition to the main analysis, subgroup analyses were conducted within additionally matched subgroups based on the presence or absence of any liver disease, viral hepatitis, previous cancer, and the use of diabetes medications, and aspirin use. Statistical analyses were conducted using SAS software, version 9.4 (SAS Institute, Cary, NC, USA). A P < 0.05 was considered as statistically significant.
Results
From the incident diabetes cohort (n 5 47,738), we selected patients who had received a diagnosis of HCC (n 5 372) and excluded those who did not meet the inclusion criteria (n 5 129). The final number of cases was 229 (Fig. 1) . The minimum, median, and maximum follow-up durations from the initial diagnosis of diabetes to HCC diagnosis were 371, 1,519, and 3,938 days, respectively (data not shown). The baseline characteristics of the 229 HCC case patients and 1,145 control patients are shown in Table 1 . Matching variables included age, sex, and the date of diagnosis of diabetes, and these were distributed evenly between case and control patients. There were more HCC patients in the group that was 60-69 years old than in the other age groups, and there were also more male HCC patients than female patients. Compared with the control group, HCC case patients had more previous cancers (OR 5 2.27, 95% CI Table 3 shows the relationship between statin use and HCC incidence among patients with and without any liver disease. Statin use significantly reduced the HCC incidence in patients with liver disease (AOR 5 0.27, 95% CI 0.14-0.50) relative to no statin use. As these patients had liver cirrhosis, the protective effect of statin increased to an AOR of 0.16 (95% CI 0.06-0.49) for patients with statin use. Otherwise, patients without any liver disease showed no statistically significant reduction of HCC risk in response to statin use, although there was a considerable reduction of HCC incidence (AOR 5 0.64, 95% CI 0.32-1.29); this reduction was Abbreviations: AOR, adjusted odds ratio; cDDDs, cumulative defined daily doses; CI, confidence interval. Individuals who had been recently diagnosed with diabetes and started statin therapy, and developed HCC afterwards were matched to controls at a five-to-one ratio on age, sex, sex, follow-up duration, and the date of the diabetes diagnosis. Adjusted for chronic viral hepatitis, liver cirrhosis, alcoholic liver disease, history of previous cancer, aspirin use, insulin use, sulfonylurea use, metformin use, thiazolidinedione use, history of chronic obstructive pulmonary disease, Charlson comorbidity score, household income level, and residential area..
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less striking than that for patients with liver disease. The effects of statins showed a dose-response relationship with AORs of 0.31 (95% CI 0.14-0.71), 0.28 (95% CI 0.08-1.05), and 0.18 (95% CI 0.06-0.60) for patients who had any liver disease with statin use of 180, 180-365, and >365 cDDDs, respectively, compared with non-users. Although patients with chronic viral hepatitis and previous cancer and those using insulin or sulfonylurea tend to have an increased risk of HCC development, as shown in Table 1 , each subgroup analysis showed the same trend of a reduced risk of HCC development in statin users compared to non-statin users in Table 3 . When patients took metformin, statin use revealed a significant protective effect on HCC development in a dosedependent manner, relative to non-users.
Discussion
In this national-based, nested case control cohort study, we examined 229 HCC cases and 1,145 controls matched by age, sex, and follow-up time, and date of T2DM diagnosis (ratio, 1:5) among 47,738 patients with incident T2DM from a baseline of 1,025,340 subjects. We demonstrated that initiating use of statin was associated with a significantly lower risk for HCC development among incident T2DM during a 12-year follow-up period after adjusting for potential confounders. Based on the subgroup analyses, patients with higher cumulative doses of statins had a statistically significant reduced risk for HCC, compared to non-users. The significant association was seen in particular among newly diagnosed T2DM patients with any liver disease relative to subjects without any liver disease.
The results of the current study were similar to those of previous studies. McGlynn et al. reported that statin use was significantly inversely associated with HCC development in the overall population (AOR 5 0.55, 95% CI 0.45 to 0.69), in a subgroup with diabetes (AOR 5 0.30, 95% CI 0.21-0.42), and in a subgroup without diabetes (AOR 5 0.66, 95% CI 0.51-0.85). 18 Moreover, although these previous studies had different study population criteria (e.g., no matching for diabetes duration, inclusion of non-incident diabetes and prior use of statin before diabetes diagnosis), statin use was associated with a significantly reduced risk for HCC in patients with diabetes, in the same context with our study.
Given that diabetes is associated with a high prevalence of dyslipidemia and metabolic syndrome, statin use is common for patients with diabetes. 12 Statins have been proven to lower cholesterol levels and reduce cardiovascular mortality, and also exhibit anticancer properties. 17, 31, 32 Diabetes is associated with a high risk of developing HCC, independent of viral hepatitis, and alcohol use, and the increasing prevalence of diabetes may contribute to the growing incidence of HCC. 6, 7, 9 Therefore, our results indicating favorable effects of statin use on HCC development in patients with diabetes are important.
The pathophysiological mechanisms that result in a reduced risk of developing HCC after statin use are not fully understood. Statins inhibit downstream products of the mevalonate pathway, mainly geranylgeranyl pyrophosphate and farnesylpyrophosphate, which are important in the activation of several cellular proteins such as the K-ras and Rho families. 33 Statins disrupt this pathway and interfere with the growth of malignant cells, resulting in apoptosis. 34 In addition, Tikkanen et al. showed that statins improved elevated serum alanine aminotransferase levels, probably attributable to hepatic steatosis. 35 Statins had beneficial effect on fatty liver, an important contributor to HCC, 11, 36 and they also reduced the risk of cirrhosis in chronic hepatitis B patients. 37 It is also unclear how statins play a beneficial role in the development of HCC in patients with diabetes. Previous studies showed that the use of insulin-sensitizers such as metformin and pioglitazone may reduce the incidence of HCC via the activation of AMPK and the inhibition of PPARg-independent regulation of nucleophosmin, respectively, while sulfonylurea or insulin use may be associated with the increased HCC risk in patients with T2DM. [38] [39] [40] The present study revealed that although patients were treated with sulfonylurea, a significant reduction in HCC incidence was associated with statin use, relative to non-statin use. Meanwhile, statins have been recently reported to have diabetogenic effects by activating hepatic autophagic flux, which is associated with upregulated hepatic gluconeogenesis. 41 Further research into the molecular mechanisms underlying the anticancer effects of statins in patients with diabetes is needed.
Here, we conducted stratified analyses in patients with and without any liver disease. A previous study found that statin use prior to a diabetes diagnosis was inversely correlated with the development of HCC in both patients with liver disease (OR 5 0.49, 95% CI 0.33-0.74) and those without any liver disease (OR 5 0.62, 95% CI 0.49-0.78). 25 However, we found that although there was a tendency towards a reduction in the risk of developing HCC among patients without any liver disease, the reduction in risk was only statistically significant for patients with liver disease, and the beneficial effect markedly increased in patients with liver cirrhosis. These somewhat different results might have been affected by the different study conditions, which were stricter in this study than in the previous study. Our study excluded those who had used statin before their diabetes diagnosis. Additionally, the definition of liver disease in our present study included not only alcoholic liver disease, chronic hepatitis, and cirrhosis but also NAFLD and autoimmune hepatitis. There have been concerns that long-term statin use may correlate with hepatotoxicity, as the central pathway of which statins target the liver and there may have been potential bias from the physicians, who were less likely to treat patients with liver disease using statins. However, several studies have reported that adverse effects were not significantly associated with long-term statin use in patients with viral hepatitis B or C, or NAFLD, and statins were actually beneficial. 19, 36, 37 We also excluded patients who had started statins within 1 year prior to HCC diagnosis, as well as those who had a latent period of <1 year after the time of diabetes diagnosis, to minimize potential bias from patients who had adverse effects from statins. Cardiovascular risk is increased in patients with metabolic syndrome-associated NAFLD, non-alcoholic steatohepatitis, viral hepatitis, and diabetes. [42] [43] [44] Some populations of patients with chronic liver disease have demonstrated that statin use is safe and effective long-term, in terms of preventing cardiovascular disease. 35, 45 Of note, in the current study, among patients with incident T2DM, including those with and without liver disease, statin use may reduce the risk of developing HCC.
The current study has several distinguishing points. To our knowledge, it is the first study of the relationship between initiation of statin and HCC development in a large sample of incident T2DM patients in an Asian population that has a high rate of HCC, using well established and validated national longitudinal database over 12 years. Also, a nested case-control study matched by age, sex, follow-up time, and date of diabetes diagnosis was conducted in the population with incident T2DM, which has a higher risk of developing HCC and a higher likelihood of using statins than a non-diabetic population. Moreover, as described above, in addition to matching variables, strict inclusion and exclusion criteria for defining incident HCC and T2DM population, new statin use after the diagnosis of T2DM, and adjustments for all potential confounders, all of which were not included in previous studies, likely provided more sophisticated and accurate results in this study.
There are several potential limitations in this study. First, although we studied a nationwide database with a total of 1,025,340 subjects, the number of case subjects and case subjects with statin use was 229 and 27, respectively, which could be considered as relatively small size. However, under reasonable range of probability of exposure in controls and OR between statin use and cancer incidence, statistical power turned out to be acceptable level (data not shown). Second, smoking and alcohol drinking are known risk factors for HCC that could not be assessed in this study, thus we used other possible surrogate variables such as a history of COPD and alcoholic liver disease, respectively, to identify these populations. Third, we could not categorize patients with chronic viral hepatitis by viral type, such as hepatitis B or C. In addition, due to lack of the laboratory or anthropometric data in the NHIS-NSC dataset, we could not approach additional data on lipid profiles or body size to evaluate more specific analysis. Lastly, in the subgroup analysis based on the type of statin, the number of subjects in each category was relatively small. In future studies, it will be important to investigate the relationship between the type of statin and the development of HCC among a large sample size of the Asian population.
In conclusion, in this nested case-control, longitudinal study, initiation of statin use reduced the risk for HCC development in new-onset T2DM, which is associated with a high incidence of HCC, acting in a dose-cumulative manner. The effect may be more dramatic in patients with liver disease than in those without any liver disease.
